What is the recommended management of cervical intraepithelial neoplasia (CIN), including the role of intralesional therapies?

Management of Cervical Intraepithelial Neoplasia (CIN)

For CIN2, active surveillance is now preferred in women under 25 years and acceptable in women 25 years and older who meet strict criteria, while CIN3 requires immediate excisional treatment, and intralesional therapies have no established role in current standard management. 1

CIN Grade-Specific Management

CIN1 (Low-Grade Lesions)

• Conservative follow-up is mandatory for all CIN1 lesions regardless of colposcopic adequacy, as over 90% regress spontaneously within 24 months 2, 3
• Follow-up protocol: repeat cytology every 6-12 months OR HPV DNA testing at 12 months 2, 3
• Return to routine screening after two consecutive negative cytology results or one negative HPV test at 12 months 2
• Treatment of CIN1 is explicitly discouraged to avoid overtreatment, cervical stenosis, and increased preterm birth risk in future pregnancies 2, 3
• Exception: CIN1 preceded by high-grade cytology (HSIL) or atypical glandular cells warrants either diagnostic excision OR observation with colposcopy and cytology every 6 months for one year 2, 4

CIN2 (Moderate-Grade Lesions)

Case Selection for Active Surveillance 1

• Women <25 years: active surveillance is preferred (though treatment remains acceptable) 1
• Women ≥25 years: active surveillance is acceptable with no upper age limit if criteria are met 1
• Mandatory requirements for surveillance:
  • Histological confirmation at baseline 1
  • Squamocolumnar junction and upper lesion limit must be fully visible 1
  • Patient willing and likely to comply with intensive monitoring 1
  • Multidisciplinary review of cytology, colposcopy, and biopsy 1
  • No immunosuppression 1
  • No previous cervical treatment 1

Active Surveillance Protocol 1

• Co-testing or HPV testing with reflex cytology plus colposcopy every 6 months 1
• Histological biopsy every 6 months if persistent/progressive disease suspected 1
• If regression evident on cytology/colposcopy but HPV-positive, biopsy at least every 12 months 1
• Treat immediately if progression occurs 1
• Offer excisional treatment at 24 months if CIN2 persists unless histological regression to CIN1 or normal is confirmed 1

Risk Factors Favoring Treatment Over Surveillance 1, 5

• Large lesion size or >2 quadrants involved 1
• Expansile CIN or significant crypt involvement 1
• HPV-16 or HPV-18 genotypes 1, 5
• High-grade index cytology (HSIL) 1, 5
• Women aged 25-40 with HPV16/18 and HSIL have 24.9% risk of occult CIN3+ and should strongly consider immediate treatment 5

Exit from Surveillance 1

• Two consecutive HPV-negative tests 12 months apart required for discharge to 3-year recall 1
• If HPV-negative at 3 years, return to routine 5-year screening intervals 1
• Any subsequent HPV-positive test requires immediate colposcopy regardless of cytology 1

CIN3 (High-Grade Lesions)

• Excisional or ablative treatment is mandatory for all adult women with CIN3 4, 6, 3
• Observation without treatment is not acceptable in adults (exceptions: adolescents and pregnancy) 4, 3
• Diagnostic excisional procedure (LEEP or cold-knife conization) is required when: 4
  • Colposcopy is unsatisfactory (junction not fully visualized)
  • Endocervical sampling reveals CIN
  • Patient has prior treatment history
• Large loop excision of the transformation zone (LEEP), high-frequency needle, or laser conization are equally effective 6
• Avoid cold-knife conization when possible due to excess risk of subsequent obstetric complications 6

Special Populations

Pregnancy 1, 2

• Colposcopy is preferred but may be deferred until ≥6 weeks postpartum 2, 4
• Therapeutic intervention is contraindicated unless invasive cancer is identified 4
• Women on active surveillance who become pregnant should be managed per pregnancy-specific guidelines with aim to rule out invasion 1
• Risk of progression to invasive cancer during pregnancy is minimal with high postpartum regression rates 2, 4

Immunosuppressed Women 1

• Should not be offered active surveillance and must be treated immediately 1

Women with Prior Treatment 1

• Should not be offered active surveillance and must be treated immediately 1

Post-Treatment Monitoring

• Cervical cytology every 4-6 months until three consecutive negative results 4
• Continue annual cytology indefinitely as recurrence may occur years later 4
• HPV testing and cytology at 6 months appears optimal for post-treatment monitoring 6

Intralesional Therapies: Historical Context Only

Intralesional therapies have no role in current standard CIN management. While historical studies from the 1990s reported intralesional beta-interferon achieving 60-80% regression rates for CIN 7, 8, and a 2009 review mentioned investigational agents like COX-2 inhibitors and novel immunotherapies 9, none of these approaches are recommended in current guidelines 1, 2, 4. Modern management relies exclusively on excisional/ablative procedures or active surveillance.

Emerging Biomarkers (Not Yet Standard Practice)

• DNA methylation testing and HPV-16/18 genotyping may support clinical decision-making where available but cannot routinely replace conventional management 1, 10
• p16 staining should not be used to upgrade CIN1 to CIN2, though absence may support CIN1 diagnosis 1
• These biomarkers show promise for risk stratification but require validation before routine clinical use 10, 11

Critical Pitfalls to Avoid

• Never treat CIN1 immediately unless preceded by high-grade cytology or glandular abnormalities 2, 3
• Never assume visible cervical lesions are benign based on normal cytology—immediate biopsy is mandatory 4
• Never perform ablative therapy without histologic confirmation of lesion grade and extent 4
• Never offer active surveillance to immunosuppressed women or those with prior treatment 1
• Never rely on endocervical curettage for CIN2 management decisions—no evidence supports its use 1
• Never use HPV testing as initial triage for LSIL—82-86% are HPV-positive, making it inefficient 2